Literature DB >> 21956776

Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages.

Qin Shao1, Ling-Hong Shen, Liu-Hua Hu, Jun Pu, Qing Jing, Ben He.   

Abstract

Macrophages crosstalk with oxidized low-density lipoprotein (oxLDL), play a critical role in the initiation, progression, and subsequently stability of atherosclerotic plaques. Statins, inhibitors of HMG CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, reduce the expression of inflammatory proteins in addition to their lipid-lowering action. However, the effect and detailed anti-inflammation mechanisms of statins in macrophages induced by oxLDL remain unclearly. In the present study, we investigated the effect of atorvastatin on inflammatory response upon oxLDL stimulation in murine macrophages and analyzed the underlying mechanisms. Tumor necrosis factor (TNF)α and monocyte chemoattractant protein-1 (MCP-1) mRNA levels were assayed by real-time PCR. The expression of cyclooxygenases-2 (COX-2) was detected by real-time PCR and Western blotting. While mitogen-activated protein kinase (MAPK) phosphorylation and IκBα degradation were determined by Western blotting. Our results showed that exposure of RAW264.7 cells to oxLDL, substantially changed the morphology of the cells and increased TNFα and MCP-1 secretion. While pretreatment with atorvastatin resulted in a significant inhibition of oxLDL-induced morphological alteration and inflammatory cytokines expression in a dose-dependent fashion. Further investigation of the molecular mechanism revealed that oxLDL upregulated the transcription and protein expression of COX-2 in a time-dependent manner. Whereas, pretreatment with atorvastatin suppressed COX-2 expression, MAPK activation and IκBα degradation. Thus, we conclude that the anti-inflammatory effect of atorvastatin is mediated through the inhibition of proinflammatory COX-2. Furthermore, suppression of ERK phosphorylation and IκBα degradation is involved in this regulation. Our findings provide a novel evidence that statins suppress inflammatory response, exert its anti-atherogenic actions via against inflammation beyond cholesterol-lowing effect.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21956776     DOI: 10.1002/jcb.23388

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  12 in total

Review 1.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

2.  Mevastatin ameliorates sphingosine 1-phosphate-induced COX-2/PGE2-dependent cell migration via FoxO1 and CREB phosphorylation and translocation.

Authors:  Chih-Kai Hsu; Chih-Chung Lin; Li-Der Hsiao; Chuen-Mao Yang
Journal:  Br J Pharmacol       Date:  2015-10-23       Impact factor: 8.739

3.  Effect of rosuvastatin on OX40L and PPAR-γ expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients.

Authors:  Jing-Yu Zhang; Bin Liu; Ya-Nan Wang; Wei-Na Zhang; Feng-Jun Wang
Journal:  J Mol Neurosci       Date:  2013-10-27       Impact factor: 3.444

4.  Polyphenols from Ilex latifolia Thunb. (a Chinese bitter tea) exert anti-atherosclerotic activity through suppressing NF-κB activation and phosphorylation of ERK1/2 in macrophages.

Authors:  Tian-Tian Zhang; Chao-Yang Zheng; Ting Hu; Jian-Guo Jiang; Jing-Wen Zhao; Wei Zhu
Journal:  Medchemcomm       Date:  2017-12-06       Impact factor: 3.597

5.  Heterozygous inactivation of the Nf1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway.

Authors:  Brian K Stansfield; Waylan K Bessler; Raghuveer Mali; Julie A Mund; Brandon Downing; Fang Li; Kara N Sarchet; Matthew R DiStasi; Simon J Conway; Reuben Kapur; David A Ingram
Journal:  Hum Mol Genet       Date:  2012-11-29       Impact factor: 6.150

6.  Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy.

Authors:  Seo Young Kwak; Sunhoo Park; Hyewon Kim; Sun-Joo Lee; Won-Suk Jang; Min-Jung Kim; SeungBum Lee; Won Il Jang; Ah Ra Kim; Eun Hye Kim; Sehwan Shim; Hyosun Jang
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

7.  Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.

Authors:  Qiaofei Liu; Yuan Li; Zheyu Niu; Yi Zong; Mengyi Wang; Lutian Yao; Zhaohui Lu; Quan Liao; Yupei Zhao
Journal:  J Exp Clin Cancer Res       Date:  2016-02-16

8.  Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway.

Authors:  Xing Liang; Li-Xia Yang; Ruiwei Guo; Yankun Shi; Xianhua Hou; Zhihua Yang; Xiaobin Zhou; Hong Liu
Journal:  Exp Ther Med       Date:  2017-01-19       Impact factor: 2.447

9.  oxLDL antibody inhibits MCP-1 release in monocytes/macrophages by regulating Ca2+ /K+ channel flow.

Authors:  Jinyu Su; Hui Zhou; Xianyan Liu; Jan Nilsson; Gunilla Nordin Fredrikson; Ming Zhao
Journal:  J Cell Mol Med       Date:  2016-12-20       Impact factor: 5.310

10.  Simvastatin impairs the induction of pulmonary fibrosis caused by a western style diet: a preliminary study.

Authors:  Peter Kruzliak; David L Hare; Vaclav Zvonicek; Jan Klimas; Anthony Zulli
Journal:  J Cell Mol Med       Date:  2015-08-25       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.